TOMI Environmental Solutions, Inc. Announces Publication of GLP Study on the Efficacy of SteraMisttm BITtm Disinfection System

BEVERLY HILLS, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ("TOMI") (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, including SteraMisttm, a hydrogen peroxide-based mist/fog registered with the U.S. Environmental Protection Agency ("EPA") for use as a hospital-healthcare disinfectant, announced inclusion of the article "Review of Necessary Practices for EPA Submission of a Hospital Disinfectant Using Good Laboratory Practice (GLP) Disinfectant Study Summaries of TOMI's SteraMisttm BITtm Disinfection System" in the Journal of The Association for Biosafety and Biosecurity (ABSA) International 2017, Vol. 22 (4) 172-180. The paper provides the first peer reviewed efficacy data for multidrug resistant organisms (MDRO's) combining equipment and solution.

The GLP paper, authored by Helene Paxton, MS, MT (ASCP), PhD, CIC, Infection Preventionist, details the stringent processes and safety requirements required by the EPA in order for all disinfectants and pesticides to be marketed for use in United States. The paper discusses the efficacy of the required log kill and other stated EPA criteria in which TOMI's SteraMisttm systems was required to show efficacy to establish a claim in the killing of bacteria, bacteria spores and the inactivating of viruses.  The paper shows efficacy for Staphylococcus aureus, MRSA, Pseudomonas aeruginosa, Influenza A flu virus (h1n1), Clostridium difficile or C. difficile spores, Salmonella enterica, Geobacillus stearothermophilus, Mycobacterium bovis, and Norovirus, a very contagious stomach and intestinal virus.

Dr. Paxton further discusses the plasma science behind TOMI's SteraMisttm technology, the hydroxyl radical produced by TOMI's novel technology which is its primary pathogen-killing agent, and the two equipment technology delivery systems that TOMI currently has on the commercial market. These nine pathogens reviewed in the paper include gram positive bacterium including spore forming, gram negative bacteria, virus species and mycobacterium.

Dr. Halden Shane, TOMI CEO, has stated, "We are very pleased to have this paper appear in such a well-respected international publication. It's important that end-users understand the rigorous EPA registration process our products went through in order to secure our hospital-healthcare disinfectant label for foggers and misting agents and it further demonstrates the validity of our efficacy claims."

About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BITtm) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BITtm uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion), represented by the TOMItm SteraMisttm brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI's products are designed to service a broad spectrum of commercial structures including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities (when not in operation), military barracks, police and fire departments, and athletic facilities. TOMI's products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.

For additional information, please visit http://www.tomimist.com/ or contact us at [email protected].

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

MEDIA RELATIONS CONTACT
Juliana deRosa
Executive Administrator
[email protected]